Holen Sie sich die Stockscreener-App
32.19
3.39%
-1.11
Praxis Precision Medicines Inc Aktie (PRAX) Neueste Nachrichten
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Praxis Precision Medicines to Participate in Upcoming April Conferences - The Manila Times
CNS Drug Developer Praxis Sets Key Investor Presentations at Needham and Piper Conferences - Stock Titan
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Praxis Grants 8,763 Shares to New Employees in Compensation Package - Stock Titan
Teacher Retirement System of Texas Invests $305,000 in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate - Yahoo Finance
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Purchased by Swiss National Bank - Defense World
Praxis Precision Medicines to Present Late-Stage Data on CNS Disorders at AAN 2025 Annual Meeting - Nasdaq
Praxis Precision Medicines to Present on Late-Stage - GlobeNewswire
Major Clinical Updates: Praxis Unveils Late-Stage Data for Epilepsy and Movement Disorders at AAN 2025 - Stock Titan
Charles Schwab Investment Management Inc. Acquires 5,840 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Sold by Bank of New York Mellon Corp - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Sold by US Bancorp DE - Defense World
HC Wainwright Has Negative Estimate for PRAX Q1 Earnings - Defense World
Praxis Precision Medicines Updates on Programs and Finances - TipRanks
New York State Common Retirement Fund Boosts Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Rhumbline Advisers Cuts Stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Praxis Precision Medicines (NASDAQ:PRAX) Hits New 1-Year Low Following Analyst Downgrade - Defense World
Praxis Adds Six New Hires With $33.55 Stock OptionsWhat's Behind This Talent Acquisition? - StockTitan
Praxis Precision Medicines to Participate in Five Upcoming Investor Conferences - GlobeNewswire
Praxis Precision price target lowered to $85 from $150 at Needham - Yahoo Finance
CNS Therapy Developer PRAX Lines Up Five Major Investor ConferencesWhat's Their 2025 Strategy? - StockTitan
Praxis: Still A 'Hold' Despite Interim Analysis Setback Of Ulixacaltamide (NASDAQ:PRAX) - Seeking Alpha
Praxis Precision Medicines (NASDAQ:PRAX) Given New $105.00 Price Target at HC Wainwright - Defense World
Praxis Precision Medicines (NASDAQ:PRAX) Price Target Cut to $85.00 by Analysts at Needham & Company LLC - Defense World
Praxis Precision Medicines (NASDAQ:PRAX) Given New $73.00 Price Target at Robert W. Baird - Defense World
Praxis Precision Medicines (NASDAQ:PRAX) Price Target Lowered to $85.00 at Truist Financial - Defense World
Praxis: A High-Risk, High-Reward Epilepsy Play Post Ulixacaltamide (Rating Upgrade) - Seeking Alpha
Analysts Cut Price Targets For Praxis Precision After Trial Setback For Essential Tremor Candidate - Benzinga India
Praxis Precision (PRAX) Stock Price Target Cut By Half - AskTraders
Praxis Precision price target lowered to $85 from $175 at Truist - TipRanks
Praxis Precision Medicines Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Praxis Precision tanks on negative ulixacaltamide news - The Pharma Letter
Deutsche Bank Adjusts Praxis Precision Medicines Price Target to $65 From $111, Maintains Buy Rating - Marketscreener.com
Assessing Praxis Precision Medicine: Insights From 5 Financial Analysts - Benzinga
Praxis Precision Medicines: A Compelling Buy Amidst Promising Pipeline Developments - TipRanks
Praxis Precision Medicines (NASDAQ:PRAX) Shares Gap Down After Earnings Miss - Defense World
Praxis Precision Medicines (PRAX) Projected to Post Quarterly Earnings on Friday - MarketBeat
Praxis cites doubts over late-stage trial success: Wedbush downgrades (update) - MSN
Praxis Precision Medicines Provides Update on Essential3 and Corporate Update - GlobeNewswire
Praxis to advance late-stage program for lead asset despite doubts over success - MSN
Praxis stock price target cut to $61 at TD Cowen By Investing.com - Investing.com Australia
Items Tagged with 'relutrigine' - BioWorld Online
Items Tagged with 'vormatrigine' - BioWorld Online
Praxis Aims To Complete ET Trial Despite Likely Primary Endpoint Miss - Citeline News & Insights
Praxis stock price target cut to $61 at TD Cowen - Investing.com India
Wedbush Downgrades Praxis Precision Medicines to Underperform From Neutral, Cuts Price Target to $26 From $57; Shares Fall - Marketscreener.com
Market Whales and Their Recent Bets on PRAX OptionsPraxis Precision Medicine (NASDAQ:PRAX) - Benzinga
H.C. Wainwright sees opportunity for quick rebound from Praxis after setback - TipRanks
Truist cuts Praxis stock target to $85, maintains buy rating By Investing.com - Investing.com South Africa
Truist cuts Praxis stock target to $85, maintains buy rating - Investing.com
Praxis Precision Medicines: Navigating Challenges and Catalysts in Epilepsy Treatment - TipRanks
Buy Rating Maintained for Praxis Precision Medicines Despite Essential3 Setback, Focus on Promising Pipeline and Strong Financial Position - TipRanks
Truist Securities Adjusts Praxis Precision Medicines Price Target to $85 From $175, Maintains Buy Rating; Shares Plunge - Marketscreener.com
Recursion Pharmaceuticals, DoubleVerify Holdings, Praxis Precision Medicines - TradingView
Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
2.65%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):